Aravive to Present Updated Modeling Data from Batiraxcept Clinical Trials at the AACR Annual Meeting
March 02 2022 - 7:00AM
Aravive, Inc. (Nasdaq: ARAV), a late clinical-stage oncology
company developing targeted therapeutics to treat metastatic
disease, will present updated exposure-response analyses from the
Phase 1b platinum-resistant ovarian cancer and Phase 1b clear cell
renal cancer trials at the American Association for Cancer Research
(AACR) annual meeting taking place between April 8-13, 2022 in New
Orleans, Louisiana. The abstract presentation at AACR will be
presented virtually.
Presentation DetailsTitle:
Exposure-Response Analysis of Batiraxcept and Application to
Recommended Phase 2 Dose in Platinum-Resistant Ovarian and Clear
Cell Renal CancersAbstract Number:
7867Presentation Type: Remote Poster
PresentationDate: April 8, 2022
About AraviveAravive, Inc. is a
late clinical-stage oncology company developing targeted
therapeutics to treat metastatic disease. Our lead product
candidate, batiraxcept (formerly AVB-500), is an ultra-high
affinity decoy protein that binds to GAS6, the sole ligand that
activates AXL, thereby inhibiting metastasis and tumor growth, and
restoring sensitivity to anti-cancer agents. Batiraxcept has been
granted Fast Track Designation by the U.S. FDA and Orphan Drug
Designation by the European Commission in platinum-resistant
recurrent ovarian cancer. Batiraxcept is in an active
registrational Phase 3 trial in platinum resistant ovarian cancer
(NCT04729608), a Phase 1b/2 trial in clear cell renal cell
carcinoma (NCT04300140), and a Phase 1b/2 trial in pancreatic
adenocarcinoma (NCT04983407). Additional information at
www.aravive.com.
Contact:Marek Ciszewski,
J.D.Vice President, Investor Relationsmarek@aravive.com (562)
373-5787
Aravive (NASDAQ:ARAV)
Historical Stock Chart
From Aug 2024 to Sep 2024
Aravive (NASDAQ:ARAV)
Historical Stock Chart
From Sep 2023 to Sep 2024